Search

everythinglearnresearchcommunity

for

Search:↓

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.

Combining mesotherapy with systemic treatments effectively improves alopecia universalis treatment.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

MK-5108 is safe and shows potential against tumors, especially alone.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Early intervention with JAK inhibitors may prevent alopecia areata progression.

Tofacitinib helped a woman regrow hair with no major side effects.

Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Secukinumab for psoriasis may cause hair loss.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Pilomatrixoma involves abnormal hair keratin production and cell death, causing debris and cysts.

Tofacitinib might be used to treat hair loss.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.